EGI
FOLD

EAM Global Investors’s Amicus Therapeutics FOLD Stock Holding History

EAM Global Investors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110,623
Closed -$1.16M – 202
2022
Q3 		$1.16M Sell
110,623
-20,618
-16% -$230K 0.31% 163
2022
Q2 		$1.41M Buy
+131,241
New +$1.08M 0.35% 148

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM Global Investors's FOLD Position: Q4 2022 in Review

EAM Global Investors sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 110,623 shares — an estimated $1.16M sold.

EAM Global Investors first reported a position in FOLD in Q2 2022 and held it in 2 quarters. The position peaked at $1.41M in Q2 2022. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • EAM Global Investors reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 110,623 Amicus Therapeutics shares in Q4 2022, an estimated $1.16M.
  • EAM Global Investors first reported a position in Amicus Therapeutics in Q2 2022 and held it in 2 quarters.
  • EAM Global Investors's Amicus Therapeutics position peaked at $1.41M in Q2 2022.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.